Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary.
This Executive Summary of the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017 Report focuses primarily on the revised and novel parts of the document. The most significant changes include: (i) the assessment of chronic obstructive pulmonary disease has been refined to separate the spirometric assessment from symptom evaluation. ABCD groups are now proposed to be derived exclusively from patient symptoms and their history of exacerbations; (ii) for each of the groups A to D, escalation strategies for pharmacological treatments are proposed; (iii) the concept of de-escalation of therapy is introduced in the treatment assessment scheme; (iv)non-pharmacological therapies are comprehensively presented and (v) the importance of co-morbid conditions in managing COPD is reviewed.
University of Marburg, Member of the German Center for Lung Research (DZL), Marburg, Germany.
Claus F
CF
Vogelmeier
Lewis Katz School of Medicine at, Temple University, Philadelphia, Pennsylvania.
Gerard J
GJ
Criner
New York-Presbyterian Hospital, Weill Cornell Medical Center, New York, New York.
Fernando J
FJ
Martinez
University of Texas Health Science Center, San Antonio, Texas.|South Texas Veterans Health Care System, San Antonio, Texas.
Antonio
A
Anzueto
National Heart and Lung Institute, Imperial College, London, United Kingdom.
Peter J
PJ
Barnes
McGill University Health Centre, McGill University, Montreal, Quebec, Canada.
Jean
J
Bourbeau
Brigham and Women's Hospital, Boston, Massachusetts.
Bartolome R
BR
Celli
State Key Lab for Respiratory Disease, Guangzhou Institute of Respiratory Disease, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Rongchang
R
Chen
University of Leuven, Leuven, Belgium.
Marc
M
Decramer
University of Modena and Reggio Emilia, Modena, Italy.
Leonardo M
LM
Fabbri
Faculty of Medicine, Flinders University, Bedford Park, South Australia, Australia.
Peter
P
Frith
Royal Devon and Exeter Hospital, Exeter, United Kingdom.
David M G
DM
Halpin
Universidad de la República, Hospital Maciel, Montevideo, Uruguay.
M Victorina
MV
López Varela
Hokkaido University School of Medicine, Sapporo, Japan.
Masaharu
M
Nishimura
Hôpital Cochin (Assistance Publique-Hôpitaux de Paris), University Paris Descartes, Paris, France.
Nicolas
N
Roche
Thorax Institute, Hospital Clinic Universitat de Barcelona, Barcelona, Spain.
Roberto
R
Rodriguez-Roisin
St. Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada.
Don D
DD
Sin
University of Manchester, Manchester, United Kingdom.
Dave
D
Singh
University Hospital, Birmingham, United Kingdom.
Robert
R
Stockley
University of Manchester, Manchester, United Kingdom.
Jørgen
J
Vestbo
National Heart and Lung Institute, Imperial College, London, United Kingdom.
Jadwiga A
JA
Wedzicha
Hospital Clínic, Universitat de Barcelona, Centro de Investigación Biomé dica en Red de Enfermedade Respiratorias, Barcelona, Spain.
Alvar
A
Agusti
D015897:Comorbidity; D018450:Disease Progression; D014943:Global Health; D006801:Humans; D017410:Practice Guidelines as Topic; D029424:Pulmonary Disease, Chronic Obstructive / Q000175:diagnosis* / Q000517:prevention & control / Q000628:therapy*; D012720:Severity of Illness Index; D013147:Spirometry; D063189:Symptom Assessment
COPD diagnosis; COPD management; COPD prevention; chronic obstructive pulmonary disease